Enbrel All Financial Data in US $ (mln)
Worldwide
 
Overview
 

Word Search (Top 10 - by date)

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials
Pfizer (March 20, 2015)
Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology
Amgen (March 17, 2015)
Samsung Bioepis Submits Marketing Authorization Application For SB2, A Remicade (Infliximab) Biosimilar Candidate, To The European Medicines Agency
Samsung Bioepis (March 13, 2015)
Novartis to Present New Late-breaking CosentyxTM Data at AAD 2015 Showing Significant Patient Benefit in Achieving Clear Skin
Novartis (March 13, 2015)
Protalex Initiates Enrollment of Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Protalex (March 12, 2015)
Pre-Filled Syringes Market Forecast 2015-2025
Gerresheimer (March 12, 2015)
Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70
Amgen (January 27, 2015)
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE
Pfizer (January 27, 2015)
European Medicines Agency Accepts Samsung Bioepis' Enbrel(R) Biosimilar Candidate, SB4, for Regulatory Review
Samsung Bioepis (January 21, 2015)
Novartis Cosentyx(TM) is the First IL-17 Inhibitor to Receive EU Approval for First-line Treatment of Moderate-to-severe Psoriasis Patients
Novartis (January 19, 2015)

Displaying 10 out of a possible 670 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Enbrel
Generic Name:   etanercept
Therapeutic Subcategory:     Other anti-rheumatics
Therapeutic Subcategory:     Anti-virals

Product Sales Summary 2012/13

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2012 2013 2013
Enbrel2 8,496 8,778 +3%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Enbrel4 411

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Enbrel

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now